Previous 10 | Next 10 |
DBV Technologies' (NASDAQ: DBVT ) Deputy CEO and Principal Financial Officer, David Schilansky, has decided to leave the company to pursue other professional opportunities. More news on: DBV Technologies S.A., DBV Technologies S.A., Healthcare stocks news, Read more ...
Montrouge, France, May 14, 2019 DBV Technologies Announces Departure of Deputy CEO David Schilansky DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that its Deputy Chief Executiv...
Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced toda...
Montrouge, France, April 30, 2019 DBV Technologies Reports March 31, 2019 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its cash and cash equivalents as of March 31,...
Montrouge, France, April 8, 2019 DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an underwritten global offering of an ...
Montrouge, France, April 5, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS) DBV Technologies (the “Compa...
DBV Technologies (NASDAQ: DBVT ) prices its global offering of an aggregate of 5,217,392 ordinary shares, for gross proceeds of ~$70.4M (~€62.7M) More news on: DBV Technologies S.A., DBV Technologies S.A., Healthcare stocks news, Stocks on the move, Read more ...
Montrouge, France, April 4, 2019 DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345...
DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced the filing of its 2018 Annual Report “Document de R...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...